Recalls / Class II
Class IID-0551-2023
Product
Glimepiride Tablets, USP 2mg, packaged in a) 30-count bottles (NDC 51655-383-52), and b)90-count bottles (NDC 51655-383-26), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.
- Brand name
- Glimepiride
- Generic name
- Glimepiride
- Active ingredient
- Glimepiride
- Route
- Oral
- NDC
- 51655-383
- FDA application
- ANDA078181
- Affected lot / code info
- a) Lot #: F106252201, Exp. Date 09/30/2024; F106252301, F106252303, Exp. Date 5/31/2025; F106252304, Exp. Date 07/31/2025 b) Lot #: F106252302, Exp. Date 07/31/2025
Why it was recalled
CGMP Deviations
Recalling firm
- Firm
- Northwind Pharmaceuticals LLC
- Manufacturer
- Northwind Health Company, LLC
- Notification channel
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
- Type
- Voluntary: Firm initiated
- Address
- 4838 Fletcher Ave Ste 1000, N/A, Indianapolis, Indiana 46203-1642
Distribution
- Quantity
- a) 230 bottles; b) 22 bottles
- Distribution pattern
- Nationwide with the United States
Timeline
- Recall initiated
- 2023-03-16
- FDA classified
- 2023-04-26
- Posted by FDA
- 2023-05-03
- Status
- Ongoing
Source: openFDA Drug Enforcement endpoint. Recall record D-0551-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.